74422
document
Intensive induction chemotherapy for small cell anaplastic carcinoma of the lung . The role of intensive induction chemotherapy in small cell cancer of the lung remains unclear . Twenty-eight newly diagnosed patients with small cell lung cancer were randomized to receive either high-dose or standard-dose cyclophosphamide , vincristine , and semustine in a trial where the dose of induction chemotherapy was the sole treatment variable . Complete responses ( CR ) were achieved in 57 % of patients receiving high-dose therapy as compared to 21 % of patients receiving standard-dose therapy ( P less than 0.05 ) . There was a higher rate of severe toxicity in the high-dose group ( P less than 0.01 ) . The overall median survival was not improved ( 36 weeks for the high-dose group vs 43 weeks for the standard-dose group ) ; however , the median survival in patients achieving CR was prolonged ( 92 weeks for the high-dose group vs 50 weeks for the standard-dose group ) . These effects were most pronounced in patients with extensive disease ; a CR after induction was achieved in five of nine patients treated with high doses but not in any of those treated with standard doses ( P less than 0.05 ) . A small group of patients appear to benefit by achieving a long-term remission with intensive induction chemotherapy , but this effect may be offset by increased morbidity .
74423
Intervention_Physical
Intensive induction chemotherapy
74424
Intervention_Pharmacological
intensive induction chemotherapy
74425
Intervention_Pharmacological
cyclophosphamide
74426
Intervention_Pharmacological
vincristine
74427
Intervention_Pharmacological
semustine
74428
Outcome_Physical
Complete responses ( CR )
74429
Outcome_Physical
severe toxicity
74430
Outcome_Mortality
overall median survival
74431
Outcome_Mortality
median survival
74432
Outcome_Physical
CR
74433
Participant_Sample-size
Twenty-eight
74434
Participant_Condition
small cell lung cancer